权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Targeting immunosuppressive adenosine in patients with metastatic non-small cell lung cancer

靶向免疫抑制腺苷治疗转移性非小细胞肺癌患者

基本信息

批准号：
10350636
负责人：
DAVID P. CARBONE
金额：
$ 55.98万
依托单位：
OHIO STATE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-02-01 至 2026-01-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10350636
关键词：
Ablation Adenosine Adenosine A2B Receptor Adverse effects Affect Affinity Animal Model Animals Applications Grants Biology Biopsy Cancer Model Cancer Patient Catabolism Cell Differentiation process Cell Fraction Cells Clinical Research Clinical Trials Collaborations Combination immunotherapy Combined Modality Therapy Data Dendritic Cells Disease Dose Effectiveness Enzymes Evaluation Generations Genetic Growth Immune Immune checkpoint inhibitor Immunity Immunologics Immunosuppression Immunotherapeutic agent Immunotherapy Impairment Institution Magnetic Resonance Imaging Malignant Neoplasms Malignant neoplasm of lung Maximum Tolerated Dose Mediating Metabolic Metabolic stress Methods Modeling Molecular Myelogenous Myeloid-derived suppressor cells Natural Killer Cells Nivolumab Non-Small-Cell Lung Carcinoma Nonmetastatic PD-1 inhibitors Pathologic Patients Peripheral Blood Mononuclear Cell Pharmacology Phase Phase Ib Clinical Trial Phase Ib Trial Phenotype Preclinical Drug Evaluation Probability Proteins Purinergic P1 Receptors Receptor Inhibition Receptor Signaling Regulation Regulatory T-Lymphocyte Resistance Role Safety Sampling Shapes Signal Transduction Spain Stress T cell response T-Lymphocyte Testing Tissues Tumor Immunity antagonist anti-PD-1 anti-PD1 antibodies anti-tumor immune response blood treatment checkpoint inhibition chemotherapy clinical application cohort design ecto-nucleotidase efficacy evaluation extracellular imaging approach imaging modality immune function immunoregulation improved novel novel strategies novel therapeutic intervention phenotypic biomarker pre-clinical preclinical study programmed cell death protein 1 receptor response therapeutic target therapy outcome tumor tumor growth tumor microenvironment

项目摘要

SUMMARY/ABSTRACT Immune checkpoint inhibitors (ICIs) have transformed the management of patients with metastatic non-small cell lung cancer (NSCLC). Unfortunately, over 50% of patients do not respond to these therapies. Combination strategies with chemotherapy-ICIs show progress, but long-term responses remain rare, pointing to the role for other tumor-associated mechanisms affecting functionality of immune cells. Adenosinergic signaling has recently emerged as a powerful immuno-metabolic regulator within the tumor microenvironment (TME) exploited by tumors to promote their growth and suppress immunity. Preclinical studies on interference with adenosine generation or signaling through A2A and A2B adenosine receptors (A2BAR) have demonstrated efficacy in relieving this immunosuppression by reducing stress in the TME and decreasing expression of key adenosine-generating enzymes, thereby enhancing efficacy of immune checkpoint inhibition. A2BAR blockade in particular enhanced anti-tumor immunity through both a reduction in myeloid-derived suppressor cell differentiation and an enhancement of the capacity of dendritic cells to evoke anti-tumor T cell responses. These findings provide strong rationale for clinical applications of A2BAR antagonists in combination with current ICIs. To determine whether disruption of A2BAR signaling has the potential to improve upon single agent PD-1 immunotherapy, we propose a phase Ib clinical trial testing the A2BAR antagonist PBF-1129 in combination with nivolumab in patients with metastatic NSCLC. The primary objective of the clinical study is to evaluate the safety and tolerability of combination PBF-1129 with nivolumab; preliminary evidence of efficacy will be evaluated in an expansion cohort. Analysis of pre- and on- treatment blood and tumor samples will be conducted to evaluate the correlation between and immunological parameters and adenosine generation and signaling, and to evaluate the efficacy of PBF-1129 in targeting adenosine-mediated immunosuppression. Finally, we intend to further elucidate mechanisms of metabolic TME and immune regulation by adenosine in pre-clinical cancer models and test the combined PBF-1129/anti-PD-1 approach to ameliorate metabolic TME using a novel imaging modality. Together, we expect that A2BAR antagonist treatment combined with nivolumab will be a safe, effective approach targeting different mechanisms of immunosuppression and tumor growth in metastatic NSCLC patients, that we will uncover immunological profiles reflective of adenosinergic signaling disruption in these patients, and that we will demonstrate the utility of a novel combined imaging approach for evaluation of adenosine targeting in the TME.

总结/摘要免疫检查点抑制剂（ICI）已经改变了转移性非小细胞肺癌患者的管理，肺癌（NSCLC）。不幸的是，超过50%的患者对这些治疗没有反应。组合化疗-ICIs策略显示出进展，但长期反应仍然罕见，指出了ICIs的作用。影响免疫细胞功能的其他肿瘤相关机制。最近，在肿瘤微环境（TME）中作为一种强大的免疫代谢调节剂出现，促进肿瘤生长，抑制免疫力。腺苷干扰的临床前研究通过A2 A和A2 B腺苷受体（A2 BAR）的产生或信号传导已经证明了在缓解这种免疫抑制通过减少TME中的应激和减少关键的腺苷生成因子的表达来实现。酶，从而增强免疫检查点抑制的功效。A2 BAR阻断作用特别增强通过骨髓来源的抑制细胞分化的减少和增强树突状细胞诱发抗肿瘤T细胞应答的能力。这些发现提供 A2 BAR拮抗剂与当前ICI组合的临床应用的强有力的理由。以确定 A2 BAR信号传导的破坏是否有可能改善单药PD-1免疫治疗，我们提出一项Ib期临床试验，测试A2 BAR拮抗剂PBF-1129与纳武利尤单抗联合治疗转移性NSCLC患者。临床研究的主要目的是评价安全性和 PBF-1129与纳武单抗的组合的耐受性;将在一项研究中评估疗效的初步证据。扩展队列。将对治疗前和治疗中的血液和肿瘤样本进行分析，以评估免疫学参数与腺苷生成和信号传导之间的相关性，并评估 PBF-1129在靶向腺苷介导的免疫抑制中的功效。最后，我们打算进一步阐明代谢TME和腺苷在临床前癌症模型中的免疫调节机制，使用新的成像方式测试组合的PBF-1129/抗PD-1方法以改善代谢性TME。总之，我们预计A2 BAR拮抗剂治疗与纳武单抗联合将是一种安全、有效的治疗方法。针对转移性肿瘤中免疫抑制和肿瘤生长不同机制的方法 NSCLC患者，我们将揭示反映腺苷能信号传导的免疫学特征我们将证明一种新的联合成像技术的实用性， TME中腺苷靶向评价的方法。